Molecular therapy for Regenerating the lost pancreatic β-cells in Diabetic patients: Pioglitazone (trade name: actos), a glucose lowering drug, promotes an insulin-sensitized state via up-regulation of its target gene Lin-28, 21/March/2017, 11.18 pm

Natural product-derived therapy for pulmonary fibrosis: Genistein decreases miR-34 expression, increases Sirtuin-1 expression, suppresses tumor suppressor p53 acetylation, prevents apoptosis in Alveolar epithelial cell (AEC), and improves pulmonary fibrosis via down regulation of its target gene, 20/March/2017, 5.40 pm
March 20, 2017
Natural product-derived therapy for Allergic rhinitis: Linalool, found in coriander leaves, and laurel among others, inhibits GM-CSF, Interleukin 13 receptor(IL-13)-Rα1, and eotaxin expression, among others, inhibits mucus production and alleviates allergic rhinitis via up regulation of its target gene, 21/March/2017, 11.37 pm
March 21, 2017
Show all

What we say

Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Regenerating the lost pancreatic β-cells in Diabetic patients: Pioglitazone (trade name: actos),  a glucose lowering drug, promotes an insulin-sensitized state via up-regulation of  its target gene Lin-28

price-300[easy_payment currency=”USD”]


From Significance of the study to Public health relevance

Given that: (1) more than 387 million people worldwide are affected by Diabetes mellitus (DM); (2) diabetic disease results in a number of health complications, including diabetic cardiomyopathy (DCM), diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy; (3) one third of people with diabetes suffer from diabetic kidney disease (DKD); and one third of them will develop kidney failure; (4) Diabetes is going to be one of the top 10 causes of death by 2030; (5) the life-long painful injection/drug treatment is required to treat DM; (6) the global economic cost spent for diabetes treatment in 2014 was little more than 600 billion US dollars, there is an urgent need to find: (i) a way to induce regeneration of adult ß-cells that were lost in DM; (ii) a cheaper alternative to the existing expensive weight-loss drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, diabetes.


From Research findings to Therapeutic opportunity:

Piogliotazone, an anti-hyperglycemic drug used in the treatment of T2DM, is one of the best selling antidiabetic drug in the US whose sales had exceeded $2.4 billion in 2008. This study provides mechanistic insight into how  how Pioglitazone functions as an anti-hyperglycemic/cardioprotective agent.

Pioglitazone, by decreasing the expression of its target geneit may (1) increase the expression of Lin-28, IGF1R, INSR, and IRS2; (2) enhance tissue repair; (3) promote regenerative capacity; (4) promote insulin sensitivity; (5) decrease myocardial infarct size; and (6) inhibit diabetic cardiomyopathy (fig 1). 

Pioglitazone increases lin-28 expression

Figure 1. Mechanistic insights into how Pioglitazone functions as an anti-hyperglycemic/cardioprotective agent. Pioglitazone, by increasing the expression of reprogramming protein Lin-28, IGFIR, INSR, and IRS2, it may promote insulin sensitivity and protect from diabetic cardiomyopathy.

Thus, pharmacological formulations encompassing Pioglitazone or its analogues either alone or in combination with other drugs” may be used to treat TIIDM and diabetic cardiomyopathy.


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Amount: $ 300#

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How does Pioglitazone promote insulin-sensitized state?

# Research cooperation

For purchase details, you may reach us at info@genomediscovery.org


References

Web: http://genomediscovery.org or http://newbioideas.com/

CitationBoominathan L, Molecular therapy for Regenerating the lost pancreatic β-cells in Diabetic patients: Pioglitazone (trade name: actos),  a glucose lowering drug, promotes an insulin-sensitized state via up-regulation of  its target gene Lin-28, 21/March/2017, 11.18 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.